(P026) Is Cause-Specific Survival Similar for Estrogen Receptor- and Progesterone Receptor-Negative Early-Stage Invasive Lobular and Invasive Ductal Cancers? A National Registry SEER Database Study

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

For early-stage breast cancer cases with ER+ and PR+ status, histology was not associated with a difference in BCSS. Alternatively, ILC cases that were ER− or PR− had an increased BCSS compared with receptor-matched IDC cases. These findings add to the growing evidence supporting ILC as a more favorable histology, which is important for guiding treatment and prognostication.

Justin M. Mann, Weisi Yan, Guojiao Wu, Dattatreyudu Nori, Akkamma Ravi; New York Presbyterian-Weill Cornell Medical Center

BACKGROUND: Invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC) are the two most common breast cancer histologies. IDC is more common and confers a worse prognosis than ILC. Biomarkers, including estrogen receptor (ER) and progesterone receptor (PR) status, improve prognostic accuracy and will likely be added to a future edition of the American Joint Committee on Cancer (AJCC) TNM classification. As a whole, patients with an ER- and PR-negative phenotype have a worse prognosis when compared with receptor-positive phenotypes. Using Surveillance, Epidemiology, and End Results (SEER) data, we performed statistical analysis to determine if receptor-matched statuses in IDC compared with ILC differ in overall outcome.

METHODS: A total of 50,658 cases of early-stage (I–IIB) breast cancer (groups = IDC and ILC) diagnosed from 1998–2002 who underwent breast conservation surgery were queried from the SEER 18 database. Patients without known ER or PR receptor status were excluded. Kaplan-Meier survival analysis and log-rank test were used to compare breast cancer cause-specific survival (BCSS).

RESULTS: There were 2,852 (5.63%) cases of ILC and 47,806 (94.37%) cases of IDC in this analysis. A total of 40,099 (79.2%) cases were ER+, and 34,901 (68.9%) cases were PR+. For ER+ cases, 60-month BCSS was 98% for ILC and 97.7% for IDC (P = .79). For ER− cases, 60-month BCSS was 95.5% for ILC and 89.7% for IDC (hazard ratio [HR] = 0.45; P = .02). For PR+ cases, 60-month BCSS was 98.3% for ILC and 97.8% for IDC (P = .35). For PR− cases, 60-month BCSS was 96.1% for ILC and 92.0% for IDC (HR = 0.77; P = .03).

CONCLUSION: For early-stage breast cancer cases with ER+ and PR+ status, histology was not associated with a difference in BCSS. Alternatively, ILC cases that were ER− or PR− had an increased BCSS compared with receptor-matched IDC cases. These findings add to the growing evidence supporting ILC as a more favorable histology, which is important for guiding treatment and prognostication.

Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Recent Videos
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Related Content